新生儿呼吸道感染产超广谱β-内酰胺酶大肠埃希菌耐药性分析

Drug resistance of extended-spectrum β-lactamases-producing escherichia coli causing respiratory tract infection in neonates

目的探讨新生儿呼吸道感染产超广谱β-内酰胺酶(ESBLs)大肠埃希菌耐药特点,指导临床用药。方法采用K-B纸片扩散法,测定大肠埃希菌对抗菌药物耐药性,同时使用双纸片协同试验确定ESBLs阳性菌株。结果 68株大肠埃希菌中产ESBLs菌56株,占82.4%,并且存在多药耐药,ESBLs大肠埃希菌对美罗培南、亚胺培南敏感性最高,分别为100.0%、98.2%,其次是头孢哌酮/舒巴坦(91.1%)。结论碳青霉烯类和头孢哌酮/舒巴坦为新生儿呼吸道感染产ESBLs大肠埃希菌感染的首选药物。

OBJECTIVE To study the characteristics of antibiotic resistance of extended-spectrum β-lactamases （ESBLs）producing Escherichia coli in newborn respiratory tract infection to guide the clinical drug application. METHODS The antibiotic resistance of E. coli to antibiotics was detected by using K-B scraps methods. ESBLs- producing strains were detected, and susceptibilities to all antibiotics were determined according to criteria of CLSI. RESULTS A total of 56 strains of ESBLs-producing bacteria were detected in 68 E. coli. Its positive rate was 82.4%. The multidrug resistance was serious in the ESBLs-producing strains E. coli. The sensitivities of ESBLs-producing E. coli to Meropenem （ 100. 0%） and imipenem （98. 2 %） were the highest. CONCLUSION Carbapenems and cefoperazone/sulbactam can be the first choice in the treatment to newborn respiratory tract infection caused by ESBLs-producing E. coli.